This invention provides the targeting of cation channels called transient receptor potential channels (“TRPC”) for control and treatment of arthritis-induced bone erosion. In certain embodiments, this invention provides a method and mode of action of N-methyl-DCPA (i.e. N-MeDCPA; N-(3,4-dichlorophenyl)-N-methyl propanamide; ELP-004) on TRPC channels. A method of restoring the balance of osteoclast to osteoblast activity in a patient having rheumatoid arthritis is provided. A method for controlling or reducing arthritis-induced bone erosion is set forth.
Inflammatory arthritis often requires treatments with serious side effects. Later in arthritis, bone erosion is a major problem that causes severe pain and debilitation. There is no small molecule drug available to specifically treat arthritis bone erosion. We show that osteoclast maturation is suppressed by blocking specific ion channels. An ion-channel antagonist, ELP-004, suppressed osteoclast maturation and strongly suppressed bone erosion in collagen-induced arthritis (CIA) in mice, even after symptoms of arthritis were measurable. In previous studies, we had focused on store-operated Ca2+ entry as the target of ELP-004, since Orail is required for osteoclast differentiation and ELP-004 blocks RANKL-induced osteoclast differentiation and SOCE at similar concentrations. However, ELP-004 blocks bone erosion in vivo at a remarkable 1000-fold higher efficacy, leading us to question the identity of the critical ion channel. To address this question, we performed a series of ELP-004 dose responses on HEK293 cells overexpressing different combinations of STIM/Orai, TRPC channels or CaV1.2. Remarkably, all TRPC channels were highly sensitive to ELP-004, leading us to consider the possibility that TRPC channels are the true target in arthritis-induced bone erosion. We are currently assessing the possibility that ELP-004 may inhibit osteoclastogenesis with higher efficacy when driven by inflammatory cytokines, both in vitro and in vivo. If so, these investigations will establish TRPC channels as critical mediators of arthritis-induced bone erosion and provide key insight into the true target of ELP-004, a patented drug currently in pre-clinical testing as a potential therapeutic.
Acute arthritis occurs in solitary sites after trauma or can be caused by infections, such as in Lyme disease, in adults or children. Usually, a cause is not identified1. Rheumatoid arthritis (RA) typically has an inflammatory pattern indistinguishable from acute arthritis, but it has a chronic relapsing course leading to the widespread destruction that involves many joints and usually requires lifelong therapy. While there are infectious causes and genetic predilections, typically RA also is idiopathic. Treatments for inflammatory arthritis include anti-metabolites, steroids, and TNF-α-blocking molecules that cause dangerous or debilitating side effects2.
In one embodiment of this invention, a method of restoring the balance of osteoclast to osteoblast activity in a patient having rheumatoid arthritis is provided comprising administering to a patient a therapeutically effective amount of a compound N-(3,4-dichlorophenyl)-N-methylpropanamide for restoring the balance of osteoclast to osteoblast activity in said patient. This method includes wherein said compound N-(3,4-dichlorophenyl)-N-methylpropanamide is administered in a pharmaceutically acceptable composition to said patient. This method includes wherein said pharmaceutically acceptable composition is administered to said patient via the oral route of administration.
In another embodiment of this invention, a method for treating arthritis-induced bone erosion in a patient is provided comprising administering to a patient a therapeutically effective amount of a compound N-(3,4-dichlorophenyl)-N-methylpropanamide for treating arthritis-induced bone erosion in said patient. This method includes wherein said compound N-(3,4-dichlorophenyl)-N-methylpropanamide is administered in a pharmaceutically acceptable composition to said patient. This method includes wherein said pharmaceutically acceptable composition is administered to said patient via the oral route of administration.
In yet another embodiment of this invention, a mode of action of N-methyl-DCPA (N-(3,4-dichlorophenyl)-N-methylpropanamide) is provided comprising targeting a transient receptor potential channel. This method comprises targeting a transient receptor potential channel (i.e. a TRPC) by administering to a patient a therapeutically effective amount of N-(3,4-dichlorophenyl)N-methylpropanamide to said patient. This method includes wherein said compound N-(3,4-dichlorophenyl)-N-methylpropanamide is administered in a pharmaceutically acceptable composition to said patient. This method includes wherein said pharmaceutically acceptable composition is administered to said patient via the oral route of administration. The transient receptor potential channel is selected from the group consisting of a TRPC3 channel, a TRPC6 channel, and a TRPC7 channel.
In another embodiment of this invention, a method of directly targeting osteoclast cells that remove old bone in a patient is provided comprising administering to a patient a therapeutically effective amount of a compound N-(3,4-dichlorophenyl)-N-methylpropanamide for directly targeting osteoclasts and restoring normal bone health in said patient. This method incudes restoring normal bone health in a patient having a disease. This method includes wherein said disease is rheumatoid arthritis. This method includes wherein said compound N-(3,4-dichlorophenyl)-N-methylpropanamide is administered in a pharmaceutically acceptable composition to said patient. This method includes wherein said pharmaceutically acceptable composition is administered to said patient via the oral route of administration.
We have extensively investigated inhibitors of the store-operated Ca2+ entry (SOCE) pathway as a target for control of bone erosion, particularly in the context of arthritis. Hence, suppressing SOCE via siRNA targeting Orail (the pore-forming unit of the store-operated Ca2+ channel) or the antagonist, 3,4-dichloropropionaniline (DCPA) reduced the formation of bone degrading osteoclasts in vitro3. Further, Orail-KO mice exhibit a significant loss of multinuclear osteoclasts and defects in bone degradation4,5. On this basis, we have assessed the possibility that DCPA and/or DCPA analogs might be effective inhibitors of bone erosion in the context of arthritis6. While this has proven to the case (data not shown), this investigation has opened new questions regarding the true identity of the DCPA target. Hence, neither DCPA nor its analogs block osteoclast differentiation at concentrations below 100 μM3, yet serum levels of these agents fail to go above 100 nM in vivo. As such, we have assessed the possibility that DCPA and its analogs may have a different target, especially within the context of arthritis.
The current investigation focuses primarily on members of the canonical transient receptor potential (TRPC) family of non-selective ion channels. Although TRPC channels have been extensively investigated as potential store-operated Ca2+ channels7-9, they are primarily activated by receptors that activate phospholipase C (PLC). Phospholipase C is a widely expressed enzyme activated by a large range of G protein-coupled receptors (GPCRs) and tyrosine kinase receptors (TKRs). Upon activation, PLC degrades phosphatidylinositol into diacylgycerol (DAG) and IP3; DAG directly activates TRPC3, 6 and 7 while loss of phosphatidylinositol is thought to be drive activity of TRPC1, 4 and 5; TRPC2 is a pseudogene in humans. As discussed below, we find that the DCPA analog N-MeDCPA inhibits TRPC channels with a 2 to 5 order of magnitude higher efficacy than SOCE, making TRPC channels the most likely candidate targets for N-MeDCPA-mediated blockade of bone erosion associated with arthritis.
N-MeDCPA (i.e. ELP-004; N-(3,4-dichlorophenyl)-N-methylpropanamide) is a haloanilide compound of Formula I:
Results
Development and safety profile of N-MeDCPA as a lead compound.
ELP-004 (N-MeDCPA) was specifically developed to preclude metabolizing to two toxic metabolites, N—OH-dichloroaniline and 6-OH-dichloroaniline. In vitro assays for toxicity caused by ELP-004 using Jurkat cells show 50% toxicity at 800 mM and <2% toxicity at 200 mM. The Contract Research Organization Illinois Institute of Toxicology Research Institute (IITRI) performed 1× escalating toxicity in rats and determined that the oral LD50 was >2.5 g/kg body weight. Excellent in vivo efficacy to prevent bone erosion associated with arthritis using two mouse models, was achieved using 150 mM intraperitoneally in an N-MeDCPA:nanoparticle preparation. Thus, ELP-004 has high potential for use as a drug to prevent or reduce bone erosion.
Inhibition of DAG-mediated TRPC activation. To determine if ELP-004 (N-MeDCPA) inhibits DAG-induced TRPC activation, HEK293 cells expressing TRPC3, TRPC6 or TRPC7 were loaded with Fura2 and incubated with ELP-004 (0 to 1 mM) for 10 minutes prior to challenging with 1-Oleoyl-2-acetyl-sn-glycerol (OAG), a membrane permeable form of diacylglycerol. OAG stimulated rapid Ca2+ entry in untreated TRPC-expressing cells (
Inhibition of GPCR-mediated TRPC activation. Since TRPC4 and TRPC5 are not activated by DAG, we utilized carbachol (Cch)-induced Sr2+ entry to determine their sensitivity to ELP-004. Since Cch drives ER Ca2+ release, Cch-induced Ca2+ entry includes both store-operated and TRPC-mediated components. To specifically measure ion entry through TRPC channels, we took advantage of the lack of ion selectivity of TRPC channel and substituted Sr2+ for Ca2+ as previously described7. As expected, Cch stimulated rapid ER Ca2+ release immediately upon addition in both TRPC4- and TRPC5-expressing cells (
Since receptor-mediated TRPC activation occurred with a much higher sensitivity than DAG-mediated TRPC activation, these data provide insight into fundamental differences in these 2 different modes of TRPC activation. Future investigations focused on defining these differences may provide new insights into precisely how PLC-coupled receptors activate TRPC channels, a question that remains largely unclear.
The other major question remaining is to define the context whereby TRPC channels would contribute to osteoclastogenesis. While physiological osteoclastogenesis is primarily driven by RANKL, in arthritis, local increases in cytokines are believed to drive osteoclastogenesis; while RANKL is not PLC-coupled, many cytokines are. As such, ongoing investigations are directed at determining if TRPC channels may contribute to arthritis-induced osteoclastogenesis driven by PLC-coupled cytokines.
Materials and Methods
Drug Synthesis—ELP-004 (N-MeDCPA) was synthesized as described in U.S. patent Ser. No. 10/682,320.
Cell Culture—HEK293 cells were grown in DMEM with 4.5 g/L glucose supplemented with 10% FBS and 1% Gentamycin (Full DMEM media; Thermo-Fisher Scientific, Waltham, MA) at 37° C. and 5% CO2. For measurements of TRPC4, TRPC5 or TRPC7 activity, cells were transiently transfected with over-expression plasmids and incubated for 2 days prior to loading with Fura2AM. HEK293 cells stably expressing either TRPC3 or TRPC6 were a generous gift from Dr. Donald L. Gill (Penn State University).
TRPC activity assay—Cells grown on glass coverslips were incubated in a cation-safe buffer (107 mM NaCl, 7.2 mM KCl, 1.2 mM MgCl2, 11.5 mM Glucose, 20 mM HEPES-NaOH, 1 mM CaCl2), pH 7.2) and loaded with Fura2-acetoxymethylester (Fura2-AM; 2 μM) for 30 min at 24° C. as previously described10,11. Cells were washed and allowed to de-esterify for a minimum of 30 min at 24° C. Ca2+/Sr2+ measurements were taken using a Leica DMI 6000B fluorescence microscope controlled by Slidebook software (Intelligent Imaging Innovations, Denver, CO). Fluorescence emission at 505 nm was monitored in response to excitation at alternating 340 nm and 380 nm wavelengths at a frequency of 0.67 Hz; intracellular Ca2+ measurements are shown at 340/380 nm ratios obtained from groups of 35-45 single cells.
ELP-004 blocks TNF-α-induced osteoclast differentiation. Mouse splenic monocytes were induced to differentiate into osteoclasts. Results were obtained of osteoclast cells after 21 days of culture with RANKL+m-CSF alone or with the addition of 100 nM ELP-004. ELP-004 inhibited development of multinucleated osteoclasts. Thus, ELP-004 inhibits osteoclastogenesis.
ELP-004 was evaluated for its ability to cross the blood brain barrier. ELP-004 does not cross the blood brain barrier. Further, ELP-004 does not cause problems with dopamine transport. Other medications, such as for example but not limited to bupropion are known to cause problems due to dopamine transporter binding. The half-life of ELP-004 when administered per os (i.e. by mouth) indicates that ELP-004 is essentially eliminated within 4 hour, given the short half-life and the relative quick time to Cmax the dopaminergic side effects would occur within 1-2 hours of administration of ELP-004. Thus, as ELP-004 does not cross the blood brain barrier, this indicates that the dopamine transporter binding is not concerning regarding ELP-004. ELP-004 has no deleterious effect on induction of CYP enzymes.
These terms and specifications, including examples, serve to describe the invention by example and not to limit the invention. Whereas particular embodiments of this invention have been described for purposes of illustration, it will be evident to those persons skilled in the art that numerous variations of the details of the present invention may be made without departing from the invention as defined herein and in the appended claims.
This utility non-provisional patent application claims the benefit of priority to U.S. Provisional Patent Application Ser. No. 63/366,585, filed Jun. 17, 2022. The entire contents of U.S. Provisional Patent Application Ser. No. 63/366,585 is incorporated by reference into this utility non-provisional patent application as if fully rewritten herein.
This invention was made with government support under Grant Nos. RO1 AR076146, RO1 DK119280, and R42 AR074812, awarded by the National Institute of Health, and Grant No. 2101 BX002490-06A1 awarded by the Department of Veterans Affairs. The government has certain rights in the invention.
Number | Date | Country | |
---|---|---|---|
63366585 | Jun 2022 | US |